Development of a comprehensive panel of antibodies against the major xenobiotic metabolising forms of cytochrome P450 in humans

Biochemical Pharmacology

Volumn 56, Issue 3, 1998, Pages 377-387

  Edwards, Robert J ^a   Adams, Delyth A ^a   Watts, Patricia S ^a   Davies, Donald S ^a   Boobis, Alan R ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Anti peptide antibodies; Cytochrome P450; Human; Liver

Indexed keywords

ANTIBODY; CYTOCHROME P450; OXYGENASE; PHENACETIN O DEETHYLASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; GEL ELECTROPHORESIS; HUMAN; HUMAN TISSUE; IMMUNIZATION; IMMUNOBLOTTING; IMMUNOREACTIVITY; LIVER; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN ISOLATION; RABBIT; TECHNIQUE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; IMMUNOBLOTTING; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; RABBITS; RECOMBINANT PROTEINS; XENOBIOTICS;

EID: 0031661240     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00033-1     Document Type: Article

References (70)

1. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW. P450 superfamily update on new sequences, gene mapping, accession numbers and nomenclature . Pharmacogenetics. 6:1996;1-42.
2. Coon MJ, Vaz AD, Bestervelt LL. Cytochrome P450 2 peroxidative reactions of diversozymes . FASEB J. 10:1996;428-434.
3. Gonzalez FJ, Lee YH. Constitutive expression of hepatic cytochrome P450 genes. FASEB J. 10:1996;1112-1117.
4. Nebert DW, McKinnon RA, Puga A. Human drug-metabolizing enzyme polymorphisms effects on risk of toxicity and cancer . DNA Cell Biol. 15:1996;273-280.
5. Thomas PE, Reik LM, Maines SL, Bandiera S, Ryan DE, Levin W. Antibodies as probes of cytochrome P450 isozymes. Adv Exp Med Biol. 197:1986;95-106.
6. Parkinson A, Gemzik B. Production and purification of antibodies against rat liver P450 enzymes. Methods Enzymol. 206:1991;233-245.
7. Gelboin HV, Cytochrome P. 450 and monoclonal antibodies. Pharmacol Rev. 45:1993;413-453.
8. Thomas PE, Reidy J, Reik LM, Ryan DE, Koop DR, Levin W. Use of monoclonal antibody probes against rat hepatic cytochromes P-450c and P-450d to detect immunochemically related isozymes in liver microsomes from different species. Arch Biochem Biophys. 235:1984;239-253.
9. Boobis AR, McQuade J, Sesardic D, Robson RT, Hayward C, Lock EA, Elcombe CR, Rose MS, Davies DS. A monoclonal antibody raised to rat liver cytochrome P-448 (form c) which recognises an epitope common to many other forms of cytochrome P-450. Biochem Pharmacol. 34:1985;1671-1681.
10. Goldfarb I, Korzekwa K, Krausz KW, Gonzalez F, Gelboin HV. Cross-reactivity of thirteen monoclonal antibodies with ten vaccinia cDNA expressed rat, mouse and human cytochrome P450s. Biochem Pharmacol. 46:1993;787-790.
11. Wrighton SA, VandenBranden M, Becker GW, Black SD, Thomas PE. Two monoclonal antibodies recognizing different epitopes on rat cytochrome IIB1 react with human IIE1. Mol Pharmacol. 41:1992;76-82.
12. Gelboin HV, Krausz KW, Goldfarb I, Buters JT, Yang SK, Gonzalez FJ, Korzekwa KR, Shou M. Inhibitory and non-inhibitory monoclonal antibodies to human cytochrome P450 3A3/4. Biochem Pharmacol. 50:1995;1841-1850.
13. Krausz KW, Yang TJ, Gonzalez FJ, Shou M, Gelboin HV. Inhibitory monoclonal antibodies to human cytochrome P450 2D6. Biochem Pharmacol. 54:1997;15-17.
14. Edwards RJ, Murray BP, Boobis AR. Antipeptide antibodies in studies of cytochromes P450IA. Methods Enzymol. 206:1991;220-233.
15. Edwards RJ, Singleton AM, Murray BP, Sesardic D, Rich KJ, Davies DS, Boobis AR. An anti-peptide antibody targeted to a specific region of rat cytochrome P-450IA2 inhibits enzyme activity. Biochem J. 266:1990;497-504.
16. Edwards RJ, Singleton AM, Murray BP, Murray S, Boobis AR, Davies DS. Identification of a functionally conserved surface region of rat cytochromes P450IA. Biochem J. 278:1991;749-757.
17. Edwards RJ, Singleton AM, Sesardic D, Boobis AR, Davies DS. Antibodies to a synthetic peptide that react specifically with a common surface region on two hydrocarbon-inducible isoenzymes of cytochrome P-450 in the rat. Biochem Pharmacol. 37:1988;3735-3741.
18. Albericio F, van Abel R, Barany G. Solid-phase synthesis of peptides with C terminal asparagine or glutamine. An effective, mild procedure based on N-alpha-fluorenylmethyloxycarbonyl (Fmoc) protection and side-chain anchoring to a tris(alkoxy)benzylamide (PAL) handle. Int J Pept Protein Res. 35:1990;284-286.
19. Breipohl G, Knolle J, Stuber W. Facile SPS of peptides having C-terminal Asn and Gln. Int J Pept Protein Res. 35:1990;281-283.
20. Boobis AR, Brodie MJ, Kahn GC, Fletcher DR, Saunders JH, Davies DS. Monooxygenase activity of human liver in microsomal fractions of needle biopsy specimens. Br J Clin Pharmacol. 9:1980;11-19.
21. Edwards RJ, Murray BP, Murray S, Schulz T, Neubert D, Gant TW, Thorgeirsson SS, Boobis AR, Davies DS. Contribution of CYP1A1 and CYP1A2 to the activation of heterocyclic amines in monkeys and human. Carcinogenesis. 15:1994;829-836.
22. Murray S, Boobis AR. An assay for paracetamol, produced by the O-deethylation of phenacetin in vitro, using gas chromatography/electron capture negative ion chemical ionization mass spectrometry. Biomed Environ Mass Spectrom. 13:1986;91-93.
23. Aitio A. A simple and sensitive assay of 7-ethoxycoumarin deethylation. Anal Biochem. 85:1978;488-491.
24. Miners JO, Smith KJ, Robson RA, McManus ME, Veronese ME, Birkett DJ. Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem Pharmacol. 37:1988;1137-1144.
25. Relling MV, Aoyama T, Gonzalez FJ, Meyer UA. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J Pharmacol Exp Ther. 252:1990;442-447.
26. Meier UT, Kronbach T, Meyer UA. Assay of mephenytoin metabolism in human liver microsomes by high-performance liquid chromatography. Anal Biochem. 151:1985;286-291.
27. Kahn GC, Boobis AR, Murray S, Brodie MJ, Davies DS. Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver. Br J Clin Pharmacol. 13:1982;637-645.
28. Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP, Yang CS. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem Res Toxicol. 3:1990;566-573.
29. Sautou V, Chopineau J, Terrisse MP, Bastide P. Solid-phase extraction of midazolam and two of its metabolites from plasma for high-performance liquid chromatographic analysis. J Chromatogr. 571:1991;298-304.
30. Gibson GG, Orton TC, Tamburini PP. Cytochrome P-450 induction by clofibrate. Purification and properties of a hepatic cytochrome P-450 relatively specific for the 12- and 11-hydroxylation of dodecanoic acid (lauric acid). Biochem J. 203:1982;161-168.
31. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes I. Evidence for its hemoprotein nature. J Biol Chem. 239:1964;2370-2378.
32. Edwards RJ, Singleton AM, Murray BP, Davies DS, Boobis AR. Short synthetic peptides exploited for reliable and specific targeting of antibodies to the C termini of cytochrome P450 enzymes. Biochem Pharmacol. 49:1995;39-47.
33. Debri K, Boobis AR, Davies DS, Edwards RJ. Distribution and induction of CYP3A1 and CYP3A2 in rat liver and extrahepatic tissues. Biochem Pharmacol. 50:1995;2047-2056.
34. Schulz TG, Thiel R, Davies DS and Edwards RJ, Identification of CYP2E1 in marmoset monkey. Biochem Biophys Acta, 1382: 287-294, 1998.
35. Schulz TG, Stahlmann R, Edwards RJ, Debri K, Davies DS, Neubert D. Enoxacin is an inducer of CYP1A2 in rat liver. Biochem Pharmacol. 50:1995;1517-1520.
36. Goldstein JA, de Morais SM. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics. 4:1994;285-299.
37. Richardson TH, Griffin KJ, Jung F, Raucy JL, Johnson EF. Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C51. Arch Biochem Biophys. 338:1997;157-164.
38. Murray BP, Edwards RJ, Murray S, Singleton AM, Davies DS, Boobis AR. Human hepatic CYP1A1 and CYP1A2 content, determined with specific anti-peptide antibodies, correlates with the mutagenic activation of PhIP. Carcinogenesis. 14:1993;585-592.
39. Edwards RJ, Murray BP, Boobis AR, Davies DS. Identification and location of alpha-helices in mammalian cytochromes P450. Biochemistry. 28:1989;3762-3770.
40. Sesardic D, Boobis AR, Edwards RJ, Davies DS. A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol. 26:1988;363-372.
41. Miles JS, McLaren AW, Forrester LM, Glancey MJ, Lang MA, Wolf CR. Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity. Biochem J. 267:1990;365-371.
42. Brian WR, Srivastava PK, Umbenhauer DR, Lloyd RS, Guengerich FP. Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. Biochemistry. 28:1989;4993-4999.
43. Veronese ME, Mackenzie PI, Doecke CJ, McManus ME, Miners JO, Birkett DJ. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Biophys Res Commun. 175:1991;1112-1118.
44. Wrighton SA, Stevens JC, Becker GW, VandenBranden M. Isolation and characterization of human liver cytochrome P450 2C19 correlation between 2C19 and S-mephenytoin 4′-hydroxylation . Arch Biochem Biophys. 306:1993;240-245.
45. Goldstein JA, Faletto MB, Romkes Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry. 33:1994;1743-1752.
46. Distlerath LM, Reilly PE, Martin MV, Davis GG, Wilkinson GR, Guengerich FP. Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem. 260:1985;9057-9067.
47. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol. 36:1989;89-96.
48. Powell PK, Wolf I, Lasker JM. Identification of CYP4A11 as the major lauric acid omega-hydroxylase in human liver microsomes. Arch Biochem Biophys. 335:1996;219-226.
49. Forrester LM, Henderson CJ, Glancey MJ, Back DJ, Park BK, Ball SE, Kitteringham NR, McLaren AW, Miles JS, Skett P, Wolf CR. Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochem J. 281:1992;359-368.
50. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals studies with liver microsomes of 30 Japanese and 30 Caucasians . J Pharmacol Exp Ther. 270:1994;414-423.
51. Imaoka S, Yamada T, Hiroi T, Hayashi K, Sakaki T, Yabusaki Y, Funae Y. Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Systematic characterization and comparison with those of the rat. Biochem Pharmacol. 51:1996;1041-1050.
52. Ono S, Hatanaka T, Hotta H, Tsutsui M, Satoh T, Gonzalez FJ. Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. Pharmacogenetics. 5:1995;143-150.
53. Gorski JC, Jones DR, Wrighton SA, Hall SD. Contribution of human CYP3A subfamily members to the 6-hydroxylation of chlorzoxazone. Xenobiotica. 27:1997;243-256.
54. Carriere V, Berthou F, Baird S, Belloc C, Beaune P, de Waziers I. Human cytochrome P450 2E1 (CYP2E1) from genotype to phenotype . Pharmacogenetics. 6:1996;203-211.
55. Adams DA, Edwards RJ, Davies DS, Boobis AR. Specific inhibition of human CYP1A2 using a targeted antibody. Biochem Pharmacol. 54:1997;189-197.
56. Fernandez-Salguero P, Hoffman SM, Cholerton S, Mohrenweiser H, Raunio H, Rautio A, Pelkonen O, Huang JD, Evans WE, Idle JR, Gonzalez FJ. A genetic polymorphism in coumarin 7-hydroxylation sequence of the human CYP2A genes and identification of variant CYP2A6 alleles . Am J Hum Genet. 57:1995;651-660.
57. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics. 6:1996;429-439.
58. Bhasker CR, Miners JO, Coulter S, Birkett DJ. Allelic and functional variability of cytochrome P4502C9. Pharmacogenetics. 7:1997;51-58.
59. Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, VandenBranden M. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol. 38:1990;207-213.
60. Jounaidi Y, Hyrailles V, Gervot L, Maurel P. Detection of CYP3A5 allelic variant a candidate for the polymorphic expression of the protein? Biochem Biophys Res Commun. 221:1996;466-470.
61. Mimura M, Baba T, Yamazaki H, Ohmori S, Inui Y, Gonzalez FJ, Guengerich FP, Shimada T. Characterization of cytochrome P-450 2B6 in human liver microsomes. Drug Metab Dispos. 21:1993;1048-1056.
62. Eaton DL, Gallagher EP, Bammler TK, Kunze KL. Role of cytochrome P4501A2 in chemical carcinogenesis implications for human variability in expression and enzyme activity . Pharmacogenetics. 5:1995;259-274.
63. Rostami-Hodjegan A, Nurminen S, Jackson PR, Tucker GT. Caffeine urinary metabolite ratios as markers of enzyme activity a theoretical assessment . Pharmacogenetics. 6:1996;121-149.
64. Hayashi S, Watanabe J, Kawajiri K. Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem Tokyo. 110:1991;559-565.
65. Hu Y, Oscarson M, Johansson I, Yue QY, Dahl ML, Tabone M, Arinco S, Albano E, Ingelman Sundberg M. Genetic polymorphism of human CYP2E1 characterization of two variant alleles . Mol Pharmacol. 51:1997;370-376.
66. McManus ME, Burgess WM, Veronese ME, Huggett A, Quattrochi LC, Tukey RH. Metabolism of 2-acetylaminofluorene and benzo(a)pyrene and activation of food-derived heterocyclic amine mutagens by human cytochromes P-450. Cancer Res. 50:1990;3367-3376.
67. Hakkola J, Pasanen M, Pelkonen O, Hukkanen J, Evisalmi S, Anttila S, Rane A, Mantyla M, Purkunen R, Saarikoski S, Tooming M, Raunio H. Expression of CYP1B1 in human adult and fetal tissues and differential inducibility of CYP1B1 and CYP1A1 by Ah receptor ligands in human placenta and cultured cells. Carcinogenesis. 18:1997;391-397.
68. McLemore TL, Adelberg S, Liu MC, McMahon NA, Yu SJ, Hubbard WC, Czerwinski M, Wood TG, Storeng R, Lubet RA, Eggleston JC, Boyd MR, Hines RN. Expression of CYP1A1 gene in patients with lung cancer evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas . J Natl Cancer Inst. 82:1990;1333-1339.
69. Hakkola J, Pasanen M, Hukkanen J, Pelkonen O, Maenpaa J, Edwards RJ, Boobis AR, Raunio H. Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta. Biochem Pharmacol. 51:1996;403-411.
70. McKinnon RA, Hall PD, Quattrochi LC, Tukey RH, McManus ME. Localization of CYP1A1 and CYP1A2 messenger RNA in normal human liver and in hepatocellular carcinoma by in situ hybridization. Hepatology. 14:1991;848-856.